Breaking News Instant updates and real-time market news.

VAR

Varian Medical

$117.16

2.57 (2.24%)

16:03
10/23/19
10/23
16:03
10/23/19
16:03

Varian Medical names Michael Bruff as CFO

Effective December 1, Gary Bischoping, Jr., currently senior vice president, Finance & chief finance officer, will take on a new role as president, Interventional Oncology Solutions; J. Michael Bruff, currently senior vice president, Finance and Investor Relations, will succeed Bischoping as senior vice president, Finance & CFO.

  • 23

    Oct

  • 15

    Nov

VAR Varian Medical
$117.16

2.57 (2.24%)

09/23/19
BRRR
09/23/19
NO CHANGE
Target $146
BRRR
Outperform
Varian Medical price target raised to $146 from $142 at Barrington
Barrington analyst Michael Petusky raised his price target for Varian Medical Systems to $146 from $142 after the company held a meeting for investors at this year's ASTRO Conference. Varian remains committed to broadening its "already significant" footprint in the cancer care space and highlighted several ways in which it will deliver value to care providers, patients and payors, Petusky tells investors in a research note. The analyst "strong" believes that the company is well positioned for any potential reimbursement changes that might come as healthcare continues to evolve towards a more value-based model. He keeps an Outperform rating on Varian Medical.
10/14/19
BTIG
10/14/19
UPGRADE
Target $130
BTIG
Buy
Varian Medical upgraded to Buy from Neutral at BTIG
BTIG analyst Sean Lavin upgraded Varian Medical to Buy from Neutral with a $130 price target. Varian shares have pulled back in recent weeks and now trade in line with the comp group, Lavin tells investors in a research note. The analyst, however, thinks the company deserves to trade at a small premium to the group since it growing both revenue and earnings faster than its peers. Further, Varian Medical has an "enviable market leading position," and is shifting its business toward faster growing, higher margin areas such as software and single-use devices, contends the analyst. He views the stock pullback as an opportunity to upgrade the shares to Buy.
10/14/19
10/14/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Neutral from Underperform at BofA/Merrill with analyst Robert Ohmes saying that he expects the "accelerated democratization" of the brand to offset the broader future challenges around "significant" third-party retail store closures and global stagnation in "performance" footwear/apparel. 2. Western Digital (WDC) upgraded to Buy from Hold at Loop Capital with analyst Ananda Baruah citing his findings that flash memory average selling prices are set to increase starting in the September and December quarters while also sustaining those increases in 2020, along with expectations of strong hyperscale HDD demand next year. 3. Varian Medical (VAR) upgraded to Buy from Neutral at BTIG with analyst Sean Lavin saying Varian shares have pulled back in recent weeks and now trade in line with the comp group. 4. Xilinx (XLNX) upgraded to Buy from Neutral at Nomura Instinet with analyst David Wong saying many risks remain for U.S. semiconductor companies, including uncertainties related to U.S./China trade issues and U.S. action against Chinese companies such as Huawei. 5. HP Enterprise (HPE) upgraded to In Line from Underperform at Evercore ISI with analyst Amit Daryanani saying he is incrementally more positive on cash flow resiliency, the Cray acquisition, recent data points that indicate H3C is performing better than other OEMs in China, and valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/22/19
RBCM
10/22/19
NO CHANGE
Target $140
RBCM
Sector Perform
Varian Medical offers favorable risk/reward ahead of earnings, says RBC Capital
RBC Capital analyst Brandon Henry keeps his Sector Perform rating and $140 price target on Varian Medical ahead of its Q4 earnings tomorrow. The analyst notes that after a 12% pullback in the stock price following Q3 results, Varian shares offer a "favorable" risk/reward and believes that the consensus estimates look "reasonable". After a $5M contribution to the company's revenue by the recently acquired assets, Henry expects that contribution to be closer to $20M in Q4, though the analyst also warns that Varian is up against its "toughest gross order comp" of the year after reporting 84 Halcyon orders in Q4 of last year.

TODAY'S FREE FLY STORIES

TNK

Teekay Tankers

$2.39

0.155 (6.94%)

06:06
11/18/19
11/18
06:06
11/18/19
06:06
Upgrade
Teekay Tankers rating change  »

Teekay Tankers upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELS

Equity Lifestyle

$69.44

0.795 (1.16%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Upgrade
Equity Lifestyle rating change  »

Equity Lifestyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

MU

Micron

$47.70

0.88 (1.88%)

, WDC

Western Digital

$50.34

-0.03 (-0.06%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Periodicals
U.S. to extend license allowing companies to do business with Huawei, NYT says »

The Trump administration…

MU

Micron

$47.70

0.88 (1.88%)

WDC

Western Digital

$50.34

-0.03 (-0.06%)

OCLR

Bought by LITE

$0.00

(0.00%)

ACIA

Acacia Communications

$67.08

0.58 (0.87%)

NPTN

NeoPhotonics

$8.57

0.08 (0.94%)

LITE

Lumentum

$68.91

0.91 (1.34%)

IIVI

II-VI

$29.45

0.19 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 03

    Dec

  • 09

    Dec

  • 09

    Dec

AVEO

Aveo Pharmaceuticals

$0.64

-0.0088 (-1.37%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Hot Stocks
Aveo Pharmaceuticals presents new data from Phase 3 TIVO-3 trial of tivozanib »

AVEO Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$23.99

2.5 (11.63%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Downgrade
Amarin rating change  »

Amarin downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

WRK

WestRock

$39.50

-0.52 (-1.30%)

06:04
11/18/19
11/18
06:04
11/18/19
06:04
Upgrade
WestRock rating change  »

WestRock upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCOM

j2 Global

$95.90

1.17 (1.24%)

06:04
11/18/19
11/18
06:04
11/18/19
06:04
Initiation
j2 Global initiated  »

j2 Global initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 04

    Dec

  • 09

    Dec

ELS

Equity Lifestyle

$69.44

0.795 (1.16%)

06:03
11/18/19
11/18
06:03
11/18/19
06:03
Upgrade
Equity Lifestyle rating change  »

Equity Lifestyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

KRTX

Karuna Therapeutics

$17.26

-0.26 (-1.48%)

06:02
11/18/19
11/18
06:02
11/18/19
06:02
Hot Stocks
Karuna Therapeutics: KarXT met primary endpoint in Phase 2 trial »

Karuna Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGFEY

Eurobank

$0.00

(0.00%)

06:01
11/18/19
11/18
06:01
11/18/19
06:01
Upgrade
Eurobank rating change  »

Eurobank upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$119.15

2.15 (1.84%)

06:01
11/18/19
11/18
06:01
11/18/19
06:01
Upgrade
Splunk rating change  »

Splunk upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CANG

Cango

$6.79

-0.05 (-0.73%)

06:00
11/18/19
11/18
06:00
11/18/19
06:00
Downgrade
Cango rating change  »

Cango downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDAY

Workday

$165.93

1.17 (0.71%)

06:00
11/18/19
11/18
06:00
11/18/19
06:00
Downgrade
Workday rating change  »

Workday downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

06:00
11/18/19
11/18
06:00
11/18/19
06:00
Hot Stocks
SoftBank-backed Yahoo Japan set to merge with Naver's Line »

SoftBank Group announced…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESTC

Elastic

$74.06

1.94 (2.69%)

05:59
11/18/19
11/18
05:59
11/18/19
05:59
Upgrade
Elastic rating change  »

Elastic upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

OKTA

Okta

$117.45

1.45 (1.25%)

05:59
11/18/19
11/18
05:59
11/18/19
05:59
Downgrade
Okta rating change  »

Okta downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

NBGIF

National Bank of Greece

$0.00

(0.00%)

05:57
11/18/19
11/18
05:57
11/18/19
05:57
Upgrade
National Bank of Greece rating change  »

National Bank of Greece…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPIRD

Piraeus Bank

$0.00

(0.00%)

05:57
11/18/19
11/18
05:57
11/18/19
05:57
Upgrade
Piraeus Bank rating change  »

Piraeus Bank upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUFG

Mitsubishi UFJ

$5.39

0.095 (1.79%)

05:56
11/18/19
11/18
05:56
11/18/19
05:56
Downgrade
Mitsubishi UFJ rating change  »

Mitsubishi UFJ downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISSDY

ISS

$0.00

(0.00%)

05:55
11/18/19
11/18
05:55
11/18/19
05:55
Downgrade
ISS rating change  »

ISS downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMKBY

AP Moller Maersk

$0.00

(0.00%)

05:53
11/18/19
11/18
05:53
11/18/19
05:53
Downgrade
AP Moller Maersk rating change  »

AP Moller Maersk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$78.05

1.18 (1.54%)

05:53
11/18/19
11/18
05:53
11/18/19
05:53
Conference/Events
T-Mobile to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 09

    Dec

BUD

AB InBev

$79.69

0.56 (0.71%)

05:52
11/18/19
11/18
05:52
11/18/19
05:52
Upgrade
AB InBev rating change  »

AB InBev upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ADDYY

Adidas

$0.00

(0.00%)

05:52
11/18/19
11/18
05:52
11/18/19
05:52
Upgrade
Adidas rating change  »

Adidas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

QD

Qudian

$7.49

-0.115 (-1.51%)

05:51
11/18/19
11/18
05:51
11/18/19
05:51
Earnings
Qudian reports Q3 EPS 47c, consensus 47c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.